January 25, 2018 / 5:14 AM / in a month

BRIEF-Generon Corp Says Successfully Concluded First Phase III Clinical Trial Of F-627

Jan 25 (Reuters) -

* GENERON SUCCESSFULLY CONCLUDES FIRST PHASE III CLINICAL TRIAL OF F-627 FOR CHEMOTHERAPY-INDUCED NEUTROPENIA

* GENERON CORP- PATIENTS TREATED WITH F-627 DEMONSTRATED SIGNIFICANTLY REDUCED DURATION OF SEVERE NEUTROPENIA COMPARED TO PATENTS IN PLACEBO GROUP ​ Source text for Eikon:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below